SCHEMBL3538865

SCHEMBL3538865

COc1ccc(-c2nc(CCl)c(C)o2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.53
PDCD4 Q53EL6 1/20 0.53
LMNA P02545 2/20 0.53
TP53 P04637 3/20 0.53
POLB P06746 3/20 0.53
MAPT P10636 5/20 0.51
PKM P14618 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 3/20 0.50
KMT2A Q03164 3/20 0.50
HSD17B10 Q99714 3/20 0.50
MEN1 O00255 2/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
GAA P10253 1/20 0.50
TSHR P16473 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25320973 0.85 MAPT (0.55) TP53MAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL201829 0.84 TARBP2 (0.53) TARBP2PDCD4LMNATP53POLB
SCHEMBL1049550 0.84 TARBP2 (0.53) TARBP2PDCD4LMNATP53POLB
SCHEMBL28137840 0.84 TARBP2 (0.53) TARBP2PDCD4LMNATP53POLB
SCHEMBL5025952 0.84 ALDH1A1 (0.48) LMNATP53POLBMAPTSMN1; SMN2
SCHEMBL4414326 0.84 POLB (0.50) LMNATP53POLBMAPTKDM4E
SCHEMBL2330165 0.83 TP53 (0.49) TARBP2LMNATP53POLBMAPT
SCHEMBL14382389 0.83 MAPT (0.56) TARBP2PDCD4LMNATP53POLB
SCHEMBL2329392 0.82 ALDH1A1 (0.61) TP53MAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL924162 0.82 HSD17B10 (0.54) TARBP2LMNATP53POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9095582-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-04 US disclosed
US-9095582-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-04 US disclosed
US-20140162981-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-06-12 US disclosed
US-20140162981-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-06-12 US disclosed
US-8440700-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-14 US disclosed
EP-2185550-B1 SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF Bayer Pharma AG (DE) 2011-11-02 EP disclosed
US-20110130377-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-06-02 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
EP-1740583-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS Sanofi-Aventis Deutschland GmbH (DE) 2007-01-10 EP disclosed
WO-2005097786-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-10-20 WO disclosed
US-5498621-A Oxazolidinedione hypoglycemic agents PFIZER INC. (US) 1996-03-12 US disclosed
US-5103014-A Antiinflammatory or/and antiallergic agent AMERICAN HOME PRODUCTS CORPORATION (US) 1992-04-07 US disclosed
EP-0428312-A2 Oxazolidinedione hypoglycemic agents PFIZER INC. (US) 1991-05-22 EP disclosed
US-4942236-A ANTIASTHMATICS AMERICAN HOME PRODUCTS CORPORATION (US) 1990-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS PPARD, PPARA, PPARG TARBP2 4685/4885PDCD4 413/4885LMNA 3215/4885
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA TARBP2 4831/4885PDCD4 936/4885LMNA 2069/4885
US-20110130377-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE AADAC, CYP4X1, AGXT TARBP2 4876/4885PDCD4 4030/4885LMNA 2430/4885
US-20140162981-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE CYP4X1, AHR, AGXT TARBP2 4883/4885PDCD4 3582/4885LMNA 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.